OPIANT PHARMACEUTICALS, INC.: 10-Q filed 2013-06-14

Name: OPIANT PHARMACEUTICALS, INC.: 10-Q filed 2013-06-14
Creator: OPIANT PHARMACEUTICALS, INC.
License: https://creativecommons.org/licenses/by/4.0/

What OPIANT PHARMACEUTICALS, INC. reported in its quarterly report filed 2013-06-14 (fiscal Q3 2013): 24 published measures, 98 facts as tagged in accession 0001144204-13-035032.

This filing

Form: 10-Q (quarterly report)
Filed: 2013-06-14
Fiscal period: fiscal Q3 2013
Accession: 0001144204-13-035032 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All OPIANT PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2013-04-30	663,175	USD
At 2012-07-31	44,976	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2013-04-30	1,189,307	USD
At 2012-07-31	663,694	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2013-04-30	-526,132	USD
At 2012-07-31	-618,718	USD
At 2011-07-31	-338,517	USD
At 2010-07-31	-637,287	USD
At 2009-07-31	290	USD
At 2008-07-31	-28,154	USD
At 2007-07-31	-10,230	USD
At 2006-07-31	23,375	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit
At 2013-04-30	609,901	USD
At 2012-07-31	20,423	USD
At 2012-04-30	25,000	USD
At 2011-07-31	51,789	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2013-02-01 to 2013-04-30	-1,099,375	USD	89
2012-08-01 to 2013-04-30	-2,736,450	USD	273
2005-06-21 to 2013-04-30	-26,665,345	USD	2871
2012-02-01 to 2012-04-30	-1,472,673	USD	90
2011-08-01 to 2012-04-30	-10,757,209	USD	274

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2012-08-01 to 2013-04-30	-569,742	USD	273
2005-06-21 to 2013-04-30	-5,056,180	USD	2871
2011-08-01 to 2012-04-30	-747,732	USD	274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2012-08-01 to 2013-04-30	1,159,220	USD	273
2005-06-21 to 2013-04-30	5,666,081	USD	2871
2011-08-01 to 2012-04-30	720,943	USD	274

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2013-02-01 to 2013-04-30	132,928,865	shares	89
2012-08-01 to 2013-04-30	132,928,865	shares	273
2012-02-01 to 2012-04-30	97,880,747	shares	90
2011-08-01 to 2012-04-30	97,880,747	shares	274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2013-02-01 to 2013-04-30	-0.01	USD/shares	89
2012-08-01 to 2013-04-30	-0.02	USD/shares	273
2012-02-01 to 2012-04-30	-0.02	USD/shares	90
2011-08-01 to 2012-04-30	-0.11	USD/shares	274

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2013-02-01 to 2013-04-30	791,833	USD	89
2012-08-01 to 2013-04-30	1,666,357	USD	273
2012-02-01 to 2012-04-30	619,166	USD	90
2011-08-01 to 2012-04-30	9,809,549	USD	274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2013-02-01 to 2013-04-30	-857,206	USD	89
2012-08-01 to 2013-04-30	-2,321,331	USD	273
2005-06-21 to 2013-04-30	-26,207,907	USD	2871
2012-02-01 to 2012-04-30	-1,451,070	USD	90
2011-08-01 to 2012-04-30	-10,731,880	USD	274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2013-04-30	639,651	USD
At 2012-07-31	20,423	USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

Period	Value	Unit	Days
2013-02-01 to 2013-04-30	177,186	USD	89
2012-08-01 to 2013-04-30	431,940	USD	273
2005-06-21 to 2013-04-30	493,329	USD	2871
2012-02-01 to 2012-04-30	3,000	USD	90
2011-08-01 to 2012-04-30	6,726	USD	274

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2013-02-01 to 2013-04-30	857,206	USD	89
2012-08-01 to 2013-04-30	2,321,331	USD	273
2005-06-21 to 2013-04-30	26,207,907	USD	2871
2012-02-01 to 2012-04-30	1,451,070	USD	90
2011-08-01 to 2012-04-30	10,731,880	USD	274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2013-02-01 to 2013-04-30	35,000	USD	89
2012-08-01 to 2013-04-30	158,679	USD	273
2005-06-21 to 2013-04-30	664,848	USD	2871
2012-02-01 to 2012-04-30	150,000	USD	90
2011-08-01 to 2012-04-30	506,169	USD	274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2013-04-30	145,805,529	shares
At 2012-07-31	126,083,416	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2013-04-30	26,043,316	USD
At 2012-07-31	23,184,094	USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

Period	Value	Unit	Days
At 2013-04-30	23,524	USD
At 2012-07-31	24,553	USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2013-02-01 to 2013-04-30	-1,123,262	USD	89
2012-08-01 to 2013-04-30	-2,786,358	USD	273
2005-06-21 to 2013-04-30	-26,715,253	USD	2871
2011-08-01 to 2012-07-31	-12,421,188	USD	366
2012-02-01 to 2012-04-30	-1,472,673	USD	90
2011-08-01 to 2012-04-30	-10,757,209	USD	274
2010-08-01 to 2011-07-31	-9,435,787	USD	365
2009-08-01 to 2010-07-31	-2,016,710	USD	365
2008-08-01 to 2009-07-31	28,444	USD	365
2007-08-01 to 2008-07-31	-17,924	USD	366
2006-08-01 to 2007-07-31	-33,605	USD	365
2005-08-01 to 2006-07-31	-32,125	USD	365

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2013-02-01 to 2013-04-30	822,206	USD	89
2012-08-01 to 2013-04-30	2,162,652	USD	273
2005-06-21 to 2013-04-30	25,504,044	USD	2871
2012-02-01 to 2012-04-30	1,301,070	USD	90
2011-08-01 to 2012-04-30	10,225,711	USD	274

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

Period	Value	Unit	Days
2012-08-01 to 2013-04-30	1,029	USD	273
2005-06-21 to 2013-04-30	3,926	USD	2871
2011-08-01 to 2012-04-30	762	USD	274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2013-02-01 to 2013-04-30	-242,169	USD	89
2012-08-01 to 2013-04-30	-415,119	USD	273
2005-06-21 to 2013-04-30	-457,438	USD	2871
2012-02-01 to 2012-04-30	-21,603	USD	90
2011-08-01 to 2012-04-30	-25,329	USD	274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

Period	Value	Unit	Days
2012-08-01 to 2013-04-30	55,000	USD	273
2005-06-21 to 2013-04-30	3,991,449	USD	2871
2011-08-01 to 2012-04-30	802,500	USD	274

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2012-08-01 to 2013-04-30	16,392	USD	273
2005-06-21 to 2013-04-30	71,889	USD	2871
2011-08-01 to 2012-04-30	6,364	USD	274

Inspect the source

Entity: OPIANT PHARMACEUTICALS, INC. / CIK 0001385508
Captured: 2026-09-22 19:47 UTC
SEC response SHA-256: 2364e629461ca2a795db263ee8044ac545282f6ca3e3ea28eb9ce90156d0a955

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001385508.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))